Professional Summary

  • My research interests are sickle cell disease (SCD) pharmacogenetics and implementation science. Currently, I am pursuing two related SCD research initiatives. Firstly, my recent tours (2014-2015) in providing clinical care to Ebola patients in Sierra Leone during the Ebola epidemic in West Africa created opportunities for a health systems strengthening SCD initiative. My principal partners in our SCD Project are Jericho Road Community Health Center (New York); Augusta University, Georgia); The Sierra Leone Sickle Cell Society (England); and the Sickle Cell Carers Awareness Network (Sierra Leone). The SCD project will establish patient cohorts in Cincinnati, Augusta, and Sierra Leone and will develop research initiatives to investigate the natural history of SCD in the patient cohorts. Currently, we have a registry of 150 pediatric patients and 38 adults with SCD. Funds from my faculty start-up package currently underwrites this project.

    As an early-stage research scientist, my current research program also explores the role of drug metabolizing enzymes and transporter to identify at-risk SCD patients for analgesic drugs failure. Enabling this goal was the award of a K01 mentored research grant from the National Institutes for Health/National Institute for Nursing Research. We are currently building a robust pharmacogenetic research program centered on the clinical translation of inherited genetic correlates that would foster the development of algorithms for personalized selection of analgesics and psycho pharmacotherapy for the individual SCD patient. To date, we have genotype and determine the frequencies of 36 drug metabolizing enzymes (including the CYP2C8, CYP2C9, and CYP2C19) and transporters involved in differential variation in drug metabolism in sickle cell disease patient cohorts. My long-term research goal is to combine elements of pharmacogenetics, proteomic, and metabolomics for integrative “personalomics” profiling of SCD patients for individualized pain management and implementation research

Education

  • Master of Arts: Bowling Green State University, 09/26/1991
  • Bachelor of Arts: University of Sierra Leone, 1987
  • Master of Arts: Bowling Green State University, 1992
  • Master of Arts: Ohio University, 1992
  • Doctor of Philosophy: Florida Atlantic University, 2001
  • Master of Public Health : University of Washington, 2006
  • Master of Nursing: University of Washington, 2008
  • Master of Nursing Science : Indiana University, 2016

Research/Clinical Interests

  • My research interests are sickle cell disease (SCD), pharmacogenetics, and health care disparities. Currently, I am pursuing two related SCD research initiatives. First, my pharmacogenetics research program is centered on the clinical translation of inherited genetic variants in drug metabolizing enzymes, drug targets and transporters (DMETs) that would foster the development of algorithms for the appropriate selection of analgesics for pain therapy in SCD patients. Second, I am developing a SCD health systems strengthening and capacity building program in Sierra Leone designed to investigate the natural history of SCD in the African environment and implementation of a clinical training and SCD preventive care program.

Credentials

  • Registered Nurse , Washington Board of Nursing , 2006
  • Cincinnati Children's Hospital & Medical
  • Hemogobinopathy Counselor, Cincinnati Children's Hospital & Medical Center, 2010
  • Ebola Clinician Training Certificate, UKAID Ebola Training Academy, 2014
  • Ebola Clinician Training Certificate, Centers for Disease Control, 2014
  • Registered Nurse, Ohio Board of Nursing , 09/31/2013

[Collapse All]

[Expand All]


Post Graduate Training/Education
Back to Top
  • Post-doctoral Fellow
    2002-2004, Indiana University, Indianapolis, Indiana, Pharmacogenetics & Public Policy
  • Registered Nurse , Washington Board of Nursing , 2006
  • Cincinnati Children's Hospital & Medical
  • Hemogobinopathy Counselor, Cincinnati Children's Hospital & Medical Center, 2010
  • Ebola Clinician Training Certificate, UKAID Ebola Training Academy, 2014
  • Ebola Clinician Training Certificate, Centers for Disease Control, 2014
  • Registered Nurse, Ohio Board of Nursing , 09/31/2013
Back to Top
Professional Affiliations
Back to Top
  • International Association of Sickle Cell Nurses and Physician Assistants
  • Board Member
  • Emergency Nurse Association
  • Member
  • American Nursing Association
  • Member
  • International Society for Psychiatric Nurses
  • Member
  • Midwest Nursing Research Society
  • Member
  • Pharmacogenetics Research Network
  • Member
  • American Pain Society, Sickle Cell Disease Pain Group
  • Member
  • Pharmacogenomics Knowledge Base
  • Member
  • International Society of Community Genetics and Genomics
  • Member
  • International Society of Nurses in Genetics
  • Member
  • Sigma Theta Tau: International Honor Society of Nursing.
  • Member
Back to Top
Positions and Work Experience
Back to Top
  • 2013-to Present,Associate Professor,College of Medicine, Department of Internal Medicine, Hematology & Oncology, Adult Comprehensive Sickle Cell Disease Center ,University of Cincinnati ,Cincinnati, Ohio
  • 2013-to Present,Associate Professor,College of Nursing ,University of Cincinnati ,Cincinnati, Ohio
  • 2013-2013,Associate Professor ,Biobehavioral Nursing, College of Nursing ,Georgia Gegents University,Augusta, Georgia
  • 2008-2013,Associate Professor ,Department of Pediatrics, Medical College of Georgia,,Georgia Gegents University,Augusta, Georgia
  • 2007-2008,Research Assistant,Personal Patient Prostate Profile Study,University of Washington,Seattle, Washington
  • 2005-2007,Research Assistant,Center for Genomic & Healthcare Equity ,University of Washington,Seattle, Washington
  • 2002-2003,Post-doctoral Fellow ,Center for Bioethics,Indiana University,Indianapolis, Indiana
  • 2002-2003,Visiting Professor,Department of Philosophy,Indiana University,Indianapolis, Indiana
  • 1998-2008,Professor (tenured/2002) ,Highline College,Des Moines, Washington
  • 1998-1998,Frederick Douglass Teaching Fellow,Department of Philosophy,West Chester University,West Chester, Pennsylvania
  • 1995-1998,Graduate Assistant,School of Public Administration,Florida Atlantic University,Boca Raton, Florida
  • 1994-1998,Adjunct Instructor,Department of Philosophy,Florida Atlantic University,Boca Raton, Florida
  • 1994-1998,Adjunct Instructor,Department of Philosophy,Florida International University,Boca Raton, Florida
  • 1994-1998,Adjunct Instructor,Arts & Science Department,Miami Dade College,Miami, Florida
  • 1992-1998,Adjunct Instructor,Social Sciences Department,Broward College,Pembroke Pines, Florida
  • 1989-1992,Research Assistant,Philosophy Documentation Center,Bowling Green State University,Bowling Green, Ohio
Back to Top
Research Grants
Back to Top
  • K01 NR01246509/01/2013-08/31/2015. National Institute of Nursing Research. Pharmacogenetic Optimization of Analgesic Prescribing in Sickle Cell Disease. Background: Allelic variability in the cytochrome P450 enzymes is an important cause of interindividual variability in analgesic drugs prescribed for sickle cell disease (SCD) pain. The potential clinical consequences of these variants range from serious toxicity to ineffective drug therapy. Despite the functional significance of CYP2D6, CYP2C9 and CYP2C19 variants, relatively fewer studies have focused on their implications for SCD pharmacotherapy. Design: We determine the CYP2C9, CYP2Cl9 and CYP2D6 allelic and genotypic frequencies in a pediatric SCD patient cohort and highlight the benefits and challenges of pharmacogenetic testing for analgesic therapy. Methods: Genomic DNA was isolated from blood samples of 30 patients, aged between 7 and 17 years. Eight variant CYP2C9 alleles, eleven CYP2CI9 alleles, and nineteen CYP2D6 alleles were genotyped across all patients using the Tag-It™ Mutation Detection Kit (Tm Bioscience, Toronto, ON, Canada) and the eSensor 2C 19 Test (GenMark Diagnostics, Carlsbad, CA, USA). Results: A total of 11 CYP2D6 alleles were detected in the cohort. The most common alleles identified were *1, *2,*10, and *17 and their frequencies were 0.339, 0.210, 0.065 and 0.161 respectively. The CYP2C19*1 frequency was 0.533. Three different CYP2C19 alleles were identified with the following frequencies:*17 (0.300), *2 (0.150) and *13 (0.0I7) respectively. For the CYP2C9 enzyme, the *1 allele frequency was 0.823.The combined frequency for all variants: *2, *3, *5, *6, *8, and *11 was 0.177. Phenotypically, 67.7% of the cohort was extensive metabolizers: 29% and 3.2 % respectively were intermediate and poor metabolizers. For the CYP2D6, phenotypes were distributed into ultra-rapid (6.5%), extensive (77.4%) and intermediate (12.9 %) metabolizers. For the CYP2C19, the metabolic phenotypes were distributed as ultra-rapid (46.7%), extensive (20%) and intermediate (33.3%) metabolizers. Conclusions: Some of the CYP2C9, 2C19, and 2D6 variant alleles implicated in the analgesic effects and toxicity of most opioids and NSAIDs analgesics are being reported for the first time among SCD patients. Our data underscore the need for pharmacokinetics studies on substrate-specific effects of variant alleles common in ethnic and racial populations with high prevalence of SCD that would potentially enable clinicians to identify patients with impaired drug metabolic profiles. . Determine distribution of drug metabolizing enzymes in a sickle cell disease patient cohort, PI, Completed.
  • 1K01NR0124652011-2015. National Institute for Nursing Research (NINR). Pharmacogenetic Optimization of Analgesic Prescribing in Sickle Cell Disease . This proposal describes a three year mentored training program creates a robust foundation in sickle cell disease (SCD) pharmacotherapy and analgesic pharmacogenetics for the development of a clinical and translational research career in SCD pain management. A customized program of study that couples didactic coursework and research training with clinical and laboratory training in SCD pathophysiology, pain management and pharmacogenetics is designed. We test the hypotheses that (1) suboptimal prescribing is associated with adverse outcomes (repeat ED visits and inpatient admissions), and (2) that lower activity CYP2C19 and CYP2D6 metabolic enzymes are associated with increased risks for repeat ED visits and inpatient admissions. Our hypotheses if confirmed would very likely stimulate studies of other measures of suboptimal pharmacotherapy (drug–drug interactions, and drug–disease interactions) for which even fewer data are available.. This project addresses pain and its management with opioid in patients with sickle cell disease. It is accepted by many in the field that management of pain in SCD populations is far from satisfactory. By linking suboptimal outpatient prescribing of opioid and deficiency in genetic metabolic capacity in SCD patients to frequent utilization of acute care resources, we may improve the quality of analgesic pharmacotherapy for these patients. - Grant, PI, Completed.
  • 07/01/2016-06/30/2017. of Nursing Dean’s Research Investigator Award College. Psychosocial vulnerabilities in a Sickle Cell Disease Patient Cohort o . Painful, acute vasoocclusive crisis (VOC), the hallmark symptom of sickle cell disease (SCD), is associated with multiple organ damage, depressive symptoms, reduced quality of life and premature death. Current analgesic therapy for SCD based on the “as-needed” opioids strategy remains unsatisfactory due to marked interindividual variation in opioid drug efficacy and side effects profiles in SCD patients. Additionally, in several cross sectional studies, greater opioid use or reduced relief from opioids for SCD pain have been linked with depressive symptoms and reduced quality of life in SCD patients underscoring the need for concomitant treatment of comorbid psychosocial health symptoms. Our objective in this exploratory, cross sectional study is to use an I-R (37 genes) assay to determine whether variation in ED visit patterns for VOC correlates with pain severity and temporality, psychosocial health profiles, and compromised ability to self-manage SCD pain effectively. We will use I-R genetic analyses, cluster analyses, and biobehavioral models to investigate associations between psychosocial symptom clusters and ED visit patterns, focusing on self-efficacy and self-management of SCD pain. Our central hypothesis is that SCD patients’ ED visit patterns, pain patterns and I-R genes may determine psychosocial vulnerabilities . Explore psychosocial vulnerabilities in a Sickle Cell Disease Patient Cohort - Grant, PI, Active.
  • 07/01/2015-06/30/2017. Emergency Medicine Foundation – Emergency Nurses Association EMF-ENA . Individualizing Patient Treatment for Sickle Cell Disease through Pharmacogenetics . Painful, acute vasoocclusive crisis (VOC), the hallmark symptom of sickle cell disease (SCD), is the primary reason for emergency department (ED) visits and hospital admissions in patients with SCD. The acute and chronic pain due to VOC is commonly undertreated or inappropriately managed due to both patient and healthcare worker fear of potential addiction and adverse effects from narcotic use. Current analgesic therapy based on the “as-needed” opioids strategy remains unsatisfactory. While the underlying genetics of SCD and mechanisms of pain due to VOC is similar in patients with the disease, there are significant differences in how patients respond to narcotic and non-narcotic treatment regimens. While some patients are able to treat their pain using oral narcotics and rarely if ever using the ED for parenteral opioids, some patients use the ED very frequently, requiring doses of opioids that exceed hospital and ED guidelines. Much of this difference in opioid usage may be attributed to mutations in drug metabolizing enzymes and transporters (DMETs) that can affect opioid metabolism leading to decreased efficacy with or without increased side effects. Our central hypothesis is that SCD patients’ ED visit patterns and pain patterns correlate positively with mutant narcotic metabolism genes. To test our central hypothesis, we will determine if mutant DMET allelic variants are associated with increased pharmacologic risk for opioid efficacy failure for VOC management in SCD patients. Our short-term goal is to provide data to support preemptive genotyping of DMET variants and to incorporate this information into current standards of care for VOC. Our long–term goal is to use genomic data from our studies to configure personalized SCD patient-specific treatment plans with varying emphasis on classic narcotic-based treatments, non-narcotic analgesic alternatives, behavioral therapies and self-care education. Our expected outcomes are consistent with the National Institute for Nursing Research mission to support research, which uses genomic biomarkers to identify at-risk individuals and assess clinical outcomes in pain and symptoms alleviation. . If our main hypothesis is supported, our study will identify the “high value” DMET allelic variant associated with higher ED utilization and poor pain control. Our findings could also inform further studies on the impact of these variants on SCD pain phenotypes and metabolic genotype-phenotype correlations. Our short-term goal is to provide warrant for the development and incorporation of preemptive genotyping of DMET variants into current standards of care for VOC. Our long–term goal is to use genomic data from our studies to configure personalized SCD patient-specific treatment plans with varying emphasis on classic narcotic-based treatments, non-narcotic analgesic alternatives, behavioral therapies and self-care education. Our expected outcomes are consistent with the National Institute for Nursing Research mission to support research, which uses genomic biomarkers to identify at-risk individuals and assess clinical outcomes in pain and symptoms alleviation - Grant, Co- PI, Active.
Back to Top
Peer Reviewed Publications (in chronological order)
Back to Top
  • Jaja, C., Barrett, N., Patel, N., Lyon, M., Xu, H., & Kutlar, A. (2016). Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.. Genetic Testing and Molecular Biomarkers. doi:10.1089/gtmb.2016.0001
  • Jaja, C., Bowman, L., Wells, L., Patel, N., Xu, H., Lyon, M., & Kutlar, A. (2015). Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management.. Clinical and Translational Science, 8 (4), 272-80. doi:10.1111/cts.12260
  • Jaja, C., Patel, N., Scott, S. A., Gibson, R., & Kutlar, A. (2014). CYP2C9 allelic variants and frequencies in a pediatric sickle cell disease cohort: implications for NSAIDs pharmacotherapy.. Clinical and Translational Science, 7 (5), 396-401. doi:10.1111/cts.12172
  • Jaja, C., Gibson, R., & Quarles, S. (2013). Advancing genomic research and reducing health disparities: what can nurse scholars do?. Journal of Nursing Scholarship : An Official Publication of Sigma Theta Tau International Honor Society of Nursing / Sigma Theta Tau, 45 (2), 202-9. doi:10.1111/j.1547-5069.2012.01482.x
  • Jaja, C. (2011). Maternal health problems and sickle cell disease. American Journal of Hematology.
  • Jaja, C., Pares-Avila, J., Wolpin, S., & Berry, D. (2010). Usability evaluation of the interactive Personal Patient Profile-Prostate decision support system with African American men.. Journal of the National Medical Association, 102 (4), 290-7.
  • Jaja, C. (2010). Cytochrome CYP2C19 Allele Frequency in Sickle Cell Disease Patients: A Pilot Study. American Journal of Hematology, 84, E30-3.
  • Jaja C. (2009). Clinical Pharmacogenetics and Analgesic Therapeutics for Sickle Cell Disease: A structured review.. American Journal of Hematology, 84, E33.
  • Jaja, C., Burke, W., Thummel, K., Edwards, K., & Veenstra, D. L. (2008). Cytochrome p450 enzyme polymorphism frequency in indigenous and native american populations: a systematic review.. Community Genetics, 11 (3), 141-9. doi:10.1159/000113876
  • Jaja C, Burke W, Thummel K, Edwards K, Veenstra D (2008). The Prevalence of P450 Drug Metabolizing Enzyme Polymorphisms in Native American Populations: A Systematic Review.. Community Genet, 11, 141-149.
  • Miller H, Jaja C (2005). Some Evidence of a Pluralistic Discipline: A Narrative Analysis of Symposium Articles.. Public Administration Review 2005, 65, 728-738.
  • Jaja, C. (2003). Why Expressive Principles won’t do it either: A philosophical perspective. . Administrative Theory and Practice, 25, 104-109.
  • Jaja C. (2003). Foretelling our pharmacogenetic future.. Nature Biotechnology, 21, 5.
Back to Top
Published Abstracts
Back to Top
  • Jaja C, Gibson R, Kuchinski A, Lyon M. (2016). Individualizing Patient Treatment for Sickle Cell Disease through Pharmacogenetics..
  • Jaja C. Patel N, Gibson R, Kutlar A. Pharmacogenetics Management of Stroke and Chronic Kidney Disease in Sickle Cell Disease..
  • Jaja C. Lyon M, Kutlar A. (2016). Genetic variability of UGT2B7, CYP3A4, CYP3A5 and CYP2B6 DMETs in a sickle cell disease patient cohort. .
  • Jenerette C, Jaja C, Brewer J. (2014). Psychometrics of Sickle Cell Disease Health-related Stigma Scale..
  • Jaja C, Bateman K, Patel N, & Kutlar A (2014). CYP2C8 allele and genotype frequencies in adult sickle cell disease patients: implications for NSAIDs metabolism..
  • Jaja C, Bowman L, Gibson R, Lyon M, & Kutlar A. (2014). CYP2C8 and CYP2C9 Preemptive genotyping in an adult sickle cell disease cohort. .
  • Jaja C, Bowman L, Gibson R, Lyon M, & Kutlar K. (2014). Frequencies of CYP2C9, CYP2C8, and CYP2C19 alleles related to antidepressants and NSAIDs metabolism in an adult sickle cell disease cohort. .
  • Jaja C. (2013). Prevalence of CYP2D6, CYP2C9 and CYP2C19 Allelic Variants in a Pediatric Sickle Cell Disease Patient Cohort: Opportunities and Challenges for Pharmacogenetic Testing. .
  • Jaja C, Kutlar A, Vega R. (2012). NSAIDs Pharmacotherapy and CYP2C9 Allele Frequency in Pediatric Sickle Cell Disease Patients..
  • Jaja C, Kutlar A, Vega R. (2012). Prevalence of CYP2D6 Allelic Variants in a Pediatric Sickle Cell Disease Patient Cohort..
  • JaJa, C. (2011). Maternal Roles, Mental Health Problems and Sickle Cell Disease. .
  • JaJa, C. (2010). Hines-Dowell S. “Cytochrome CYP2C19 Allele Frequency in Sickle Cell Disease Patients: A Pilot Study. .
  • JaJa, C. (2010). Genomics Medicine and Health Disparities: Delineating Spaces for Critical Public Policy Engagement. .
  • JaJa, C. (2009). Hines-Dowell S. Pharmacogenetics Testing for Analgesic Therapeutics in Sickle Cell Disease Pain Management. .
  • JaJa, C. (2009). Clinical Pharmacogenetics and Analgesic Therapeutics for Sickle Cell Disease: A structured review..
  • JaJa, C. (2008). Murthy V. Neonatal genetic screening for malignant hyperthermia: Technical and Ethical Considerations. .
  • JaJa, C. (2008). Clinical Pharmacogenetics and Sickle Cell Disease Therapeutics. .
  • Jaja C, Burke W, Thummel K, Edward K, Veeenstra D. (2006). The Prevalence of P450 Drug Metabolizing Enzyme Polymorphisms in Native American Populations: A Systematic Review. .
  • JaJa, C. (2006). Is a genetic test for malignant hyperthermia ready for prime time? Evaluation of the ryanodine receptor (RYR1) gene mutation test. .
  • Jaja C, Burke W, Thummel K. (2005). Perceptions of genetic risk and clinical utility of diagnostic testing: A case study of malignant hyperthermia. .
  • Jaja C, Meslin E, Flockhart D. (2003). Assessing Institutional Review Boards Experience with Pharmacogenetics Research. .
Back to Top
Other Publications
Back to Top
  • JaJa, C. (2001). Art and Life in Africa. Teaching History. A Journal of Method, 26, 1. .
  • JaJa, C. (1999). Southern Horrors and Other Writings: The Anti-lynching Campaign of Ida B. Wells, 1892-1900.. Teaching History: A Journal of Methods , 24:1. .
  • JaJa, C. (1998). Democratization and the Postcolonial State. . African Philosophy , 11:2. .
  • JaJa, C. (1998). Hobbes’s Theory of Colonialism and the African Colonial Experience: Structural and Programmatic Affinities. . The American Philosophical Association Newsletter, 97, 2-6. .
  • JaJa, C. (1997). African Colonial State in Comparative Perspective. . Journal of Third World Studies. .
  • JaJa, C. (1997). The Hermeneutics of African Philosophy. . The American Philosophical Association Newsletters, 96, 2. .
  • JaJa, C. (1996). African Philosophy: Selected Readings.. Teaching Philosophy , 19, 2-4. .
  • JaJa, C. (1996). Africans in the Americas. . Teaching History: A Journal of Methods. .
  • JaJa, C. (1992). African Philosophy: The Essential Reading.. Dialogue, 34, 2-3. .
Back to Top
Invited Presentations
Back to Top
  • JaJa, C. (11-2014). Feasibility of Preemptive Genotyping of CYP2C8, CYP2C9 and CYP2C19 Enzymes for Rational Pharmacotherapy in Sickle Cell Disease..International Society of Nurses in Genetics Annual Meeting, ,Scottsdale, AZ. National
  • Jaja C, Barrett N, Lyon M, Kutlar A. (08-2016). Pharmacogenetics Guidelines for Management of Sickle Cell Disease Comorbidities..International Society of Nurses in Genetics, Annual Congress ,Dublin, Ireland. International
  • Jaja C, Bowman L, Patel N, Xu N, Kutlar A (07-2016). Pulmonary Hypertension as a sickle cell disease emergency: Is there a role for preemptive pharmacogenetics testing?.6th International African Symposium on Sickle Cell Disease. ,Accra, Ghana. International
Back to Top
Colloquium
Back to Top
  • JaJa, C. (04-2014). Frequencies of CYP2C9, CYP2C8, and CYP2C19 alleles related to antidepressants and NSAID metabolism in an adult sickle cell disease cohort. .Network of Minority Health Researchers Annual Meeting, NIH ,Bethesda, MD. National
  • Jaja C, Barrett N, Gibson R, Kutlar A. (01-2016). Drug Metabolizing Enzymes and Transporters Frequencies in a Sickle Cell Disease Patient Cohort. .4th Caribbean Congress on Sickle Cell Disease Conference. ,Kingston, Jamaica.. International
  • JaJa, C. (07-2010). Cytochrome CYP2C19 Allele Frequency in Sickle Cell Disease Patients: A Pilot Study. .2010 Gordon Conference on Drug Metabolism ,Holderness School, Holderness, NH.. Conference. National
  • JaJa, C. (11-2008). Clinical Pharmacogenetics and Sickle Cell Disease Therapeutics..International Society of Nurses in Genetics annual Meeting ,Philadelphia, PA. Professional Meeting. National
  • JaJa, C. (11-2015). DMET Variants Involved in Opioid Analgesics Metabolism for Sickle Cell Disease Pain Management..International Society of Nurses in Genetics Annual Congress. ,Pittsburg, Pennsylvania.. Professional Meeting. Regional
  • JaJa, C. (04-2015). Clinical Ethics and the Ebola Virus Disease: Perspective from an Ebola Treatment Unit in Sierra Leone..TaSkR – Bioethics Conference ,Indiana University, Indiana, Bloomington, IN. Conference. Regional
  • JaJa, C. (04-2015). Clinical Utility of Preemptive Genotyping of CYP2C19 allelic variants in Sickle Cell Disease Patient..Midwest Nursing Research Society ,Indianapolis, IN. Professional Meeting. Regional
  • JaJa, C. (02-2015). There is No Emergency in the Ebola Treatment Unit.Grand Round ,Georgia Regents University, Augusta, GA. Other Institution. Regional
  • JaJa, C. (04-2016). Personal Perspectives and Lessons from Ebola.UCCOM Global Health Interest Group and Partners in Health Engage Cincinnati ,University of Cincinnati, Cincinnati, Ohio. UC. Local
  • JaJa, C. (04-2016). Analgesic Pharmacogenetics in Sickle Cell Disease.Children’s Hospital Medical Center Genetic Counseling Progam ,Cincinnati, Ohio. Other Institution. Local
  • JaJa, C. (11-2015). Working in an Ebola Treatment Center in Sierra Leone: Experience of a Clinical Volunteer..Children’s Hospital Medical Center Global Health Seminar ,Cincinnati, Ohio. Other Institution. Local
  • JaJa, C. (04-2015). Human Factors and Ebola Preparedness: Lessons for the Frontline. .Ebola Vigilance for Regional Preparedness Planners Workshop ,Cincinnati, Ohio. UC. Local
Back to Top
Lectures
Back to Top
  • JaJa, C. (03-1999). African Philosophy and American Philosophy: Two Philosophical Enterprises Resting on Mistakes.”. Conference of the National Association for Humanities Education ,Jacksonville, Florida. Conference. National
  • JaJa, C. (04-1996). “Who is Black? Defining Blackness in the United States.” . A public lecture ,Broward County Regional Library, Pembroke Pines. Professional Meeting. National
Back to Top
Paper Presentations
Back to Top
  • JaJa, C. (01-2000). Outlining a Practical Use of Academic Public Administration Theorizing. 13th Annual Conference of the Public Administration Theory Network ,Fort Lauderdale, Florida. Conference. National
  • JaJa, C. (03-1998). Public Administration: How to Understand its Theory and Practice Pragmatically. . 11th National Conference of the Public Administration Theory Network ,Colorado Springs, Colorado. Conference. National
  • JaJa, C. (09-1997). Spatial Situatedness and Public Administration Theorizing. . Southeastern Conference for Public Administration ,Knoxville, Tennessee. Conference. National
  • JaJa, C. (03-1997). Hobbes’s Leviathan, Political Legitimacy and Theories of Colonialism.. 10th National Conference of the Public Administration Theory Network ,Richmond, Virginia. . Conference. National
  • JaJa, C. (03-2000). “African Philosophy as a Practice.” . African Philosophy Conference ,Hamline University, St. Paul, Minnesota. Other Institution. National
  • JaJa, C. (08-2000). “Global Perspectives Project: A Multidisciplinary Approach to Teaching Global Issues.” . American Association of Philosophy Teachers Biennial Workshop-Conference on Teaching Philosophy ,Alverno College, Milwaukee, Wisconsin. Other Institution. National
  • JaJa, C. (06-1991). “African Philosophy as Applied Philosophy.”. National Council for Black Studies Third Summer Faculty Institute ,The Ohio State University, Columbus, Ohio. Other Institution. National
Back to Top
Symposium
Back to Top
  • JaJa, C. (04-2013). Prevalence of CYP2D6, CYP2C9 and CYP2C19 Allelic Variants in a Pediatric Sickle Cell Disease Patients.. 7th SCD Annual Symposium and Scientific Meeting. ,Miami, FL. . National
Back to Top
Recent Awards/Honors
Back to Top
  • .Substance Abuse and Mental Health Services Administration Minority Fellowship Program (SAMHSA) & American Nurses Association (ANA) Fellowship Program ,2015
  • Translational Science Research Presentation Award Network of Minority Research Investigators (NMRI) .National Institute of Diabetes & Digestive & Kidney Diseases,2014
  • Excellence in Nursing Research Sigma Theta Tau..Honor Society of Nursing, Beta Omicron Chapter ,2013
  • Health Disparities Loan Repayment Program($45000).NIH/NIMHD,2012
  • Carl Storm Underrepresented Minority Fellowship (CSURM) .Gordon Conference,2010
  • Information Technology Gateway Project Master Teacher .Northeast Tech Prep Consortium,2009
  • Rockefeller Foundation Dissertation Fellowship.Rockefeller Foundation,1999
  • SVHE Teaching Fellowship.Society for Value in Higher Education,1999
  • Frederick Douglass Summer Teaching Fellowship.West Chester University,1998
  • Graduate Students’ Summer Teaching Fellowship.American Philosophical Association & American Association of Philosophy Teachers ,1998
  • Individual Making Personal Achievement and Contribution Award.Florida Atlantic University,1996
  • Outstanding Academic Performance in International Studies Award.Ohio University,1991
  • Ford Foundation Summer Fellowship.National Council for Black Studies,1991
  • Future Research Leaders Conference (FRLC) Fellow.National Institutes for Health (NIH),2016
Back to Top
Student Advising
Back to Top
  • Natalie Merilus (2014). Promoting Self- Management in Young Adults with Sickle Cell Disease: An Educational Toolkit. Completed ,Master. Committee Member.
  • Caroline MorrisonSelf-management by Adolescents and Young Adults Following a Stem Cell Transplant.. ,Doctoral. Committee Member.
  • Cheryl Robinson (2012). Metabolic Syndrome and Health Disparities among Black and White Men with Prostate Cancer Undergoing GnRH Therapy. Completed ,Doctoral. Committee Member.
Back to Top
Courses Taught
Back to Top
  • New Course Developed ,Theory Construction, Analysis & Evaluation . Graduate
  • Old Course Revised ,NPHD 9006 Nursing Inquiry II. Graduate
  • New Course Developed ,PMSN7030C Accelerated Concepts of Community/Public Health Nursing . Graduate
  • Old Course Revised ,NPHD 9035 Dissertation Seminar. Graduate
  • Regular Course ,NPHD 9035 Dissertation Seminar II . Graduate
  • Regular Course ,NPHD 9006 Nursing Inquiry II . Graduate
  • Regular Course ,NPHD 9034 Dissertation Seminar I . Graduate
  • Regular Course ,NPHS 9005 Nursing Inquiry I. Graduate
  • Regular Course ,NURS 6990: Scientific and Clinical Inquiry . Graduate
  • Regular Course ,NURS 8500: Philosophy of Nursing Science. Graduate
  • Regular Course ,NURS 7100: Integrated Health Care: Community . Graduate
  • Regular Course ,NURS 4415: Community Health Nursing . Undergraduate
  • Regular Course ,NURS 8100: Seminar in Academic Career Development.
  • Regular Course ,NURS 4991 Population Health. Undergraduate
  • Regular Course ,NURS 6300: Introduction to Epidemiology and Biostatistics. Graduate
  • Regular Course ,NURS 4306: Research & Evidence Based Practice . Undergraduate
  • Regular Course ,NURS 7226: Examination of Practice . Graduate
  • Regular Course ,Phil 100: Introduction to Philosophy .
  • Regular Course ,Phil 110: Introduction to Ethics.
  • Regular Course ,Phil 120: Symbolic Logic .
  • Regular Course ,Geog 100: Introduction to Geography.
  • Regular Course ,Phil 125: Race and Racism .
  • Regular Course ,Phil 150: Bioethics.
  • Regular Course ,HIS 120: African History.
  • Regular Course ,GEOG 140: African Geography.
  • Regular Course ,Phil 200: Reasoning and Symbolic Lo.
  • Regular Course ,Phil 215: Ethics and Moral Reasoning .
  • Regular Course ,Phil 2010: Introduction to Philosophy.
  • Regular Course ,Phil 3132: Logical Reasoning.
  • Regular Course ,Phil 4661: Ethics .
  • Regular Course ,Phil 2100: Introduction to Logic.
  • Regular Course ,Phil 2103: Critical Thinking .
  • Regular Course ,Phil 2011: Philosophical Analysis.
Back to Top
Service
Back to Top
  • University/College Service ,Research and Scholarly Activities Council ,Elected Member ,College(2014-to Present).
  • University/College Service ,Faculty Search Committee ,Elected Member ,College(2014-to Present).
  • University/College Service ,University Library Committee ,Elected Member ,University(2016-to Present).
  • University/College Service ,University of Cincinnati ,UC International Affairs Committee ,Elected Member ,University(2016-to Present).
  • University/College Service ,Diversity and Inclusion in the Undergraduate Curriculum Initiative ,Member ,University(2016-to Present).
  • Community Service ,Journal of Blood Medicine ,Reviewer(2016).
  • Community Service ,Planning Committee for the 2016 NMRI Mid-West Regional Workshop ,Member(2016).
  • Community Service ,International Society of Nurses in Genetics ,2016 ISONG World Congress "Integrating Genetics Across Nursing Practice , Reviewer(2016).
  • Community Service ,Foundation for Sickle Cell Disease Research ,10th SCD Research and Educational Symposium , Reviewer(2016).
  • Community Service ,Midwest Nursing Research Society ,Midwest Nursing Research Society 40th Annual Research Conference , Reviewer(2016).
  • Community Service ,Southwest Ohio District Science and Engineering Expo ,Poster Judge ,Other(2016).
  • Community Service ,American Nurses Foundation ,Nursing Research Grant Reviewer ,Reviewer(2016).
  • Community Service ,Midwest Nursing Research Society ,Midcareer Scholars Task Force ,Member(2016).
  • Community Service ,International Association of Sickle Cell Nurses and Physician Assistants ,IASCNAPA Board of Directors and Executive Committee ,Member(2016).
  • Community Service ,Develop Africa Board of Directors ,Dream Home Orphanage ,Member(2016).
  • Community Service ,International Society of Nurses in Genetics ,Ethics and Public Policy Committee ,Co-Chair(2015).
  • Community Service ,Network of Minority Research Investigators ,Oversight Committee ,Member(2015-2017).
  • Community Service ,American Academy of Nursing ,2014 State of the Science Congress on Nursing Research , Reviewer(2014).
  • ,Journal of Medical Genetics and Genomics ,Member(2014-to Present).
  • ,Journal of Pain Research , Reviewer(2013-to Present).
  • Community Service ,Western Journal of Nursing Research , Reviewer(2013-to Present).
  • Community Service ,African Journal of Hematology , Reviewer(2012-to Present).
  • Community Service ,Pharmacogenomics and Personalized Medicine , Reviewer(2012-to Present).
  • Community Service ,Educational Research Journal , Reviewer(2011-to Present).
  • ,Journal of Health and Medical Informatics ,Outside(2010-to Present).
Back to Top